Lymphocytic variant hypereosinophilic syndromes.
A large body of evidence establishing the existence of an underlying T-cell disorder in a subset of patients fulfilling hypereosinophilic syndrome (HES) diagnostic criteria has accumulated over the past decade, resulting in the definition of a novel HES variant termed "lymphocytic" HES. Although end-organ complications of hypereosinophilia are generally benign, with predominant cutaneous manifestations, long-term prognosis is overshadowed by an increased risk of developing T-cell lymphoma, as a result of malignant transformation of aberrant T cells years after HES diagnosis. Therapeutic strategies should target pathogenic T cells in addition to eosinophils, but the practical implications remain largely unexplored.
Roufosse
Florence
F
Department of Internal Medicine, Erasme Hospital, Université Libre de Bruxelles, 808 Route de Lennik, B-1070 Brussels, Belgium. froufoss@ulb.ac.be
Cogan
Elie
E
Goldman
Michel
M
D015703:Antigens, CD / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000503:physiopathology; D016176:T-Lymphocyte Subsets / Q000502:physiology*
D015703:Antigens, CD; D016207:Cytokines